PH12020552240A1 - Compounds - Google Patents
CompoundsInfo
- Publication number
- PH12020552240A1 PH12020552240A1 PH12020552240A PH12020552240A PH12020552240A1 PH 12020552240 A1 PH12020552240 A1 PH 12020552240A1 PH 12020552240 A PH12020552240 A PH 12020552240A PH 12020552240 A PH12020552240 A PH 12020552240A PH 12020552240 A1 PH12020552240 A1 PH 12020552240A1
- Authority
- PH
- Philippines
- Prior art keywords
- formula
- compounds
- hydrogen
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
- C07K7/62—Polymyxins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a polymyxin compound of formula (I) and salts, solvates and protected forms thereof, pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds and compositions in methods of treatment, such as methods for the treatment of microbial infections. The compounds of formula (I) are represented thus: formula (I) wherein -R15 is a group: formula (II) and -R16 is hydrogen; -R17 is hydrogen; -L- is a covalent bond or methylene; and -Ar is optionally substituted aryl. The groups -X-, -R1, -R2, -R3, -R4, and -R8 are as defined herein.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862689602P | 2018-06-25 | 2018-06-25 | |
| PCT/EP2019/066819 WO2020002325A1 (en) | 2018-06-25 | 2019-06-25 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12020552240A1 true PH12020552240A1 (en) | 2021-08-16 |
Family
ID=67107423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12020552240A PH12020552240A1 (en) | 2018-06-25 | 2020-12-21 | Compounds |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11459357B2 (en) |
| EP (2) | EP3810633B1 (en) |
| JP (1) | JP7488774B2 (en) |
| KR (1) | KR20210054500A (en) |
| AR (1) | AR116663A1 (en) |
| AU (2) | AU2019294261B2 (en) |
| BR (1) | BR112020026663A2 (en) |
| CA (1) | CA3103158A1 (en) |
| CO (1) | CO2020016080A2 (en) |
| DK (1) | DK3810633T3 (en) |
| EA (1) | EA202092819A1 (en) |
| ES (1) | ES2971732T3 (en) |
| FI (1) | FI3810633T3 (en) |
| HR (1) | HRP20240028T1 (en) |
| HU (1) | HUE065134T2 (en) |
| IL (1) | IL279620A (en) |
| LT (1) | LT3810633T (en) |
| MA (1) | MA52946B1 (en) |
| MD (1) | MD3810633T2 (en) |
| MX (1) | MX2020013811A (en) |
| PH (1) | PH12020552240A1 (en) |
| PL (1) | PL3810633T3 (en) |
| PT (1) | PT3810633T (en) |
| RS (1) | RS65128B1 (en) |
| SG (1) | SG11202012747VA (en) |
| SI (1) | SI3810633T1 (en) |
| TW (1) | TW202019949A (en) |
| WO (1) | WO2020002325A1 (en) |
| ZA (1) | ZA202301937B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016083531A1 (en) * | 2014-11-26 | 2016-06-02 | New Pharma Licence Holdings Limited | Compounds |
| LT3810633T (en) * | 2018-06-25 | 2024-01-10 | Spero Therapeutics, Inc. | Compounds |
| WO2022098950A1 (en) | 2020-11-06 | 2022-05-12 | Spero Therapeutics, Inc. | Compounds |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2128617A (en) | 1982-10-06 | 1984-05-02 | Martti Vaara | Polypeptides for use in antibacterial therapy |
| AU7753787A (en) | 1986-08-06 | 1988-02-24 | Jean-Luc Fauchere | Production of covalent-linked conjugates from an antibiotic and a non-toxic derivative of polymyxine b |
| US20010021697A1 (en) | 1987-09-14 | 2001-09-13 | Henning Lowenstein | Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components |
| TW274552B (en) | 1992-05-26 | 1996-04-21 | Hoechst Ag | |
| US5767068A (en) | 1997-02-13 | 1998-06-16 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
| CA2540742A1 (en) | 2003-09-30 | 2005-04-14 | Terry Hicks | Compositions and methods for treating burns |
| US20060004185A1 (en) | 2004-07-01 | 2006-01-05 | Leese Richard A | Peptide antibiotics and peptide intermediates for their prepartion |
| WO2008017734A1 (en) | 2006-08-11 | 2008-02-14 | Northern Antibiotics Oy | Polymyxin derivatives and uses thereof |
| US7807637B2 (en) | 2006-08-11 | 2010-10-05 | Northern Antibiotics Oy | Polymyxin derivatives and uses thereof |
| FI20085469A0 (en) | 2008-02-08 | 2008-05-16 | Northern Antibiotics Oy | Polymyxin derivatives with short fatty acid tails and their uses |
| US8193148B2 (en) | 2008-02-08 | 2012-06-05 | Northern Antibiotics Ltd. | Short fatty acid tail polymyxin derivatives and uses thereof |
| US8329645B2 (en) | 2008-02-08 | 2012-12-11 | Northern Antibiotics Ltd. | Polymyxin derivatives and uses thereof |
| ES2334547B1 (en) | 2008-09-10 | 2010-12-03 | Universidad De Barcelona | ANTIBACTERIAL PEPTIDIC COMPOUNDS. |
| WO2010075416A1 (en) | 2008-12-23 | 2010-07-01 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
| CN101851270A (en) | 2009-04-03 | 2010-10-06 | 梁浩 | Polymyxin derivative and preparation method thereof |
| WO2010130007A1 (en) | 2009-05-14 | 2010-11-18 | Monash University | Antimicrobial compounds |
| US8415307B1 (en) | 2010-06-23 | 2013-04-09 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
| WO2012051663A1 (en) | 2010-10-21 | 2012-04-26 | Monash University | Antimicrobial compounds |
| WO2012168820A1 (en) * | 2011-06-08 | 2012-12-13 | Pfizer Inc. | Polymyxin derivatives useful as antibacterial agents |
| WO2013072695A1 (en) | 2011-11-18 | 2013-05-23 | Novacta Biosystems Limited | Polymyxin derivatives |
| KR102354902B1 (en) | 2013-05-22 | 2022-01-24 | 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 | Polymyxin derivatives and their use in combination therapy together with different antibiotics |
| TWI709575B (en) | 2014-03-11 | 2020-11-11 | 美商斯佩羅治療學股份有限公司 | Polymyxin derivatives and their use in combination therapy together with different antibiotics |
| CN106414480B (en) | 2014-04-01 | 2020-08-04 | 莫纳什大学 | Polymyxin derivatives as antimicrobial compounds |
| WO2016083531A1 (en) | 2014-11-26 | 2016-06-02 | New Pharma Licence Holdings Limited | Compounds |
| WO2016166103A1 (en) * | 2015-04-13 | 2016-10-20 | Xellia Pharmaceuticals Aps | Polymyxin derivatives |
| JP7367950B2 (en) * | 2015-09-29 | 2023-10-24 | モナッシュ ユニバーシティ | Antibacterial polymyxin derivative compounds |
| LT3810633T (en) * | 2018-06-25 | 2024-01-10 | Spero Therapeutics, Inc. | Compounds |
| WO2020014501A1 (en) | 2018-07-11 | 2020-01-16 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of bacterial infections |
-
2019
- 2019-06-25 LT LTEPPCT/EP2019/066819T patent/LT3810633T/en unknown
- 2019-06-25 CA CA3103158A patent/CA3103158A1/en active Pending
- 2019-06-25 BR BR112020026663-9A patent/BR112020026663A2/en unknown
- 2019-06-25 DK DK19734346.0T patent/DK3810633T3/en active
- 2019-06-25 SG SG11202012747VA patent/SG11202012747VA/en unknown
- 2019-06-25 PL PL19734346.0T patent/PL3810633T3/en unknown
- 2019-06-25 EP EP19734346.0A patent/EP3810633B1/en active Active
- 2019-06-25 RS RS20240128A patent/RS65128B1/en unknown
- 2019-06-25 MA MA52946A patent/MA52946B1/en unknown
- 2019-06-25 US US17/253,426 patent/US11459357B2/en active Active
- 2019-06-25 ES ES19734346T patent/ES2971732T3/en active Active
- 2019-06-25 AU AU2019294261A patent/AU2019294261B2/en active Active
- 2019-06-25 KR KR1020217000402A patent/KR20210054500A/en unknown
- 2019-06-25 HR HRP20240028TT patent/HRP20240028T1/en unknown
- 2019-06-25 JP JP2020571762A patent/JP7488774B2/en active Active
- 2019-06-25 SI SI201930707T patent/SI3810633T1/en unknown
- 2019-06-25 WO PCT/EP2019/066819 patent/WO2020002325A1/en active Application Filing
- 2019-06-25 AR ARP190101764A patent/AR116663A1/en unknown
- 2019-06-25 EA EA202092819A patent/EA202092819A1/en unknown
- 2019-06-25 PT PT197343460T patent/PT3810633T/en unknown
- 2019-06-25 TW TW108122117A patent/TW202019949A/en unknown
- 2019-06-25 MD MDE20210390T patent/MD3810633T2/en unknown
- 2019-06-25 HU HUE19734346A patent/HUE065134T2/en unknown
- 2019-06-25 MX MX2020013811A patent/MX2020013811A/en unknown
- 2019-06-25 FI FIEP19734346.0T patent/FI3810633T3/en active
- 2019-06-25 EP EP23215457.5A patent/EP4316504A3/en active Pending
-
2020
- 2020-12-21 IL IL279620A patent/IL279620A/en unknown
- 2020-12-21 PH PH12020552240A patent/PH12020552240A1/en unknown
- 2020-12-22 CO CONC2020/0016080A patent/CO2020016080A2/en unknown
-
2022
- 2022-08-23 US US17/893,944 patent/US20230012121A1/en active Pending
-
2023
- 2023-02-06 ZA ZA2023/01937A patent/ZA202301937B/en unknown
-
2024
- 2024-05-21 AU AU2024203362A patent/AU2024203362A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202301937B (en) | Compounds | |
| PH12021500014A1 (en) | Fused ring compounds | |
| PH12021551065A1 (en) | Fused ring compounds | |
| EA202091491A1 (en) | NEW BENZYLAMINE SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | |
| PH12016501338A1 (en) | Indazole compounds as irak4 inhibitors | |
| MX2018010878A (en) | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections. | |
| EA202090604A1 (en) | CHROMANMONOBACTAM COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | |
| EA202193015A1 (en) | CDK INHIBITORS | |
| BR112017000246A2 (en) | compound, pharmaceutically acceptable salt of a compound, pharmaceutical composition, and use of a compound or salt | |
| EA201300617A1 (en) | β-LACTAM COMPOUNDS AS β-LACTAMASE INHIBITORS AND THEIR APPLICATION | |
| BR112018074985A2 (en) | antibacterial compositions | |
| MX2020000576A (en) | Chemical compounds. | |
| CO2019013254A2 (en) | 5,6-fused bicyclic compounds and compositions for the treatment of parasitic diseases | |
| EA202190064A1 (en) | CYANOTRIAZOLE COMPOUNDS AND VARIANTS OF THEIR APPLICATION | |
| MX2018016339A (en) | Anti-infective heterocyclic compounds and uses thereof. | |
| MX2020004842A (en) | Anti-infective heterocyclic compounds and uses thereof. | |
| EA201992370A1 (en) | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | |
| PH12021551058A1 (en) | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | |
| PH12019502277A1 (en) | Crystalline forms of (s)-afoxolaner | |
| PH12019502261A1 (en) | Therapeutic or prophylactic agent for peripheral neuropathies | |
| MX2022011593A (en) | Crystalline forms of a tyk2 inhibitor. | |
| WO2019046465A3 (en) | Therapeutic indoles | |
| MX2019009362A (en) | Novel heterocyclic compounds and their use in preventing or treating bacterial infections. | |
| CY1119316T1 (en) | Hydrochloride Salts of an Antibiotic Union | |
| MX2022006776A (en) | Ophthalmic pharmaceutical compositions. |